Hormone Refractory Prostate Cancer clinical trials

Explore recruiting hormone refractory prostate cancer clinical trials.

Recruiting hormone refractory prostate cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hormone Refractory Prostate Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Safety, pharmacokinetics, and preliminary efficacy of VIR-5500 (AMX-500) in prostate cancer

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with an androgen receptor pathway inhibitor (ARPI) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)

Germany, France, Spain, Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of [177Lu]LU-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

Italy, France, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Randomized, Double-blind, Placebo-controlled Study of JNJ-78278343, a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer

France, Belgium, Spain, Poland, Italy, Netherlands +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Ebastine in combination with docetaxel or cabazitaxel as a treatment for metastatic castration-resistant prostate cancer

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I, open-label, multi-center study of radiation dosimetry, safety, and tolerability of extended lutetium (177Lu) vipivotide tetraxetan treatment in chemo-naïve adults with metastatic castration-resistant prostate cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) study

Spain, Germany, Netherlands

Human Pharmacology (Phase I)- Other EU CTIS Study details

Hormone Refractory Prostate Cancer trials by city

Hormone Refractory Prostate Cancer in Toronto Hormone Refractory Prostate Cancer in Vancouver Hormone Refractory Prostate Cancer in Montreal Hormone Refractory Prostate Cancer in Calgary Hormone Refractory Prostate Cancer in Edmonton Hormone Refractory Prostate Cancer in Ottawa Hormone Refractory Prostate Cancer in Winnipeg Hormone Refractory Prostate Cancer in Quebec City Hormone Refractory Prostate Cancer in Hamilton Hormone Refractory Prostate Cancer in Kitchener Hormone Refractory Prostate Cancer in London Hormone Refractory Prostate Cancer in Halifax Hormone Refractory Prostate Cancer in New York Hormone Refractory Prostate Cancer in Los Angeles Hormone Refractory Prostate Cancer in Chicago Hormone Refractory Prostate Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease